ANG1005
- Generic Name
- ANG1005
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
ANG1005 in Leptomeningeal Disease From Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 150
- Registration Number
- NCT03613181
Expanded Access to ANG1005 for Individual Patients
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2016-06-07
- Lead Sponsor
- Angiochem Inc
- Registration Number
- NCT02755987
- Locations
- ๐บ๐ธ
UC Irvine Health, Orange, California, United States
๐บ๐ธUniveristy of Texas Health Science Center in San Antonio, San Antonio, Texas, United States
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 72
- Registration Number
- NCT02048059
- Locations
- ๐บ๐ธ
University of California - LAC Medical Center, Los Angeles, California, United States
๐บ๐ธGRU Cancer Center - Georgia Regents University, Augusta, Georgia, United States
๐บ๐ธUniversity of Maryland - Greenebaum Cancer Center, Baltimore, Maryland, United States
ANG1005 in Patients With Recurrent High-Grade Glioma
- Conditions
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 73
- Registration Number
- NCT01967810
- Locations
- ๐บ๐ธ
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
๐บ๐ธNorris Cotton Cancer Center, Lebanon, New Hampshire, United States
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 63
- Registration Number
- NCT00539344
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธHenry Ford Health System, Detroit, Michigan, United States
๐บ๐ธIrving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, United States
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Angiochem Inc
- Target Recruit Count
- 56
- Registration Number
- NCT00539383
- Locations
- ๐บ๐ธ
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUT Health Science Center, Cancer Therapy and Research Center, San Antonio, Texas, United States
๐บ๐ธGabrail Cancer Center, Canton, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.